Also trades as: 2137.HK (HKSE) · $vol 0M
BRIBF OTC
Brii Biosciences Limited
1W: +0.0%
1M: +0.0%
3M: -13.0%
YTD: -30.4%
1Y: -46.0%
3Y: -89.6%
$0.13
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$18M
-63.7% ▼
5Y CAGR: -26.1%
Gross Profit
$0
-100.0% ▼
Operating Income
-$296M
+26.7% ▲
Net Income
-$217M
+57.3% ▲
EPS (Diluted)
$-0.30
+57.1% ▲
EBITDA
-$290M
+27.7% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $93M | $52M | $617K | $50M | $18M |
| YoY Growth | +12.6% | -44.2% | -98.8% | +7993.4% | -63.7% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $93M | $52M | $617K | $50M | $0 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 0.0% |
| R&D Expenses | $495M | $441M | $403M | $250M | $207M |
| SG&A Expenses | $79M | $80M | $57M | $204M | $102M |
| Operating Expenses | $703M | $566M | $545M | $454M | $308M |
| Operating Income | -$610M | -$514M | -$544M | -$404M | -$296M |
| Operating Margin | -659.7% | -995.3% | -88217.3% | -808.7% | -1632.6% |
| Interest Expense | $1M | $851K | $494K | $0 | $2M |
| Income Before Tax | -$4.2B | -$490M | -$184M | -$512M | -$216M |
| Tax Expense | $0 | $0 | $0 | $0 | $2M |
| Net Income | -$4.1B | -$484M | -$175M | -$508M | -$217M |
| Net Margin | -4452.3% | -938.1% | -28335.3% | -1017.6% | -1196.6% |
| EPS (Diluted) | $-9.48 | $-0.67 | $-0.24 | $-0.70 | $-0.30 |
| EBITDA | -$603M | -$504M | -$168M | -$402M | -$290M |
| Shares Outstanding | 439M | 723M | 728M | 730M | 722M |